Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idelalisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 18/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.78 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.78 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.78 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | PRKDC | P78527 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idelalisib SCHEMBL19499808 | 1.00 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| Idelalisib SCHEMBL29422886 | 1.00 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| Idelalisib SCHEMBL356400 | 1.00 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| Idelalisib SCHEMBL29354482 | 1.00 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| Idelalisib SCHEMBL16822787 | 0.99 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| Idelalisib SCHEMBL16822786 | 0.99 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16678026 | 0.94 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16678062 | 0.94 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677317 | 0.94 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677535 | 0.93 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025469-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | claimed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | claimed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | claimed |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | claimed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | claimed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | claimed |
| EP-2916868-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS S A (CH) | 2022-05-11 | — | — | EP | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2005117889-A1 | METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC | ICOS CORPORATION (US) | 2005-12-15 | — | — | WO | claimed |
| WO-2005113556-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | claimed |
| WO-2005112935-A1 | PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS | VANDERBILT UNIVERSITY (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | ICOS CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2005016349-A1 | METHODS OF INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005016348-A1 | METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | PI4KB, PIK3CD, PIK3CA | PIK3CD 2/4885PIK3CG 7/4885PIK3CB 4/4885 |
| US-20250025469-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | PIK3CD 29/4885PIK3CG 30/4885PIK3CB 23/4885 |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | DPYD, KRAS, ABL1 | PIK3CD 154/4885PIK3CG 433/4885PIK3CB 167/4885 |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | FLT4, KDR, PDGFRB | PIK3CD 6/4885PIK3CG 13/4885PIK3CB 14/4885 |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | PI4KB, PI4KA, PIK3CD | PIK3CD 3/4885PIK3CG 10/4885PIK3CB 6/4885 |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | MCL1, NFATC1, MKI67 | PIK3CD 25/4885PIK3CG 57/4885PIK3CB 37/4885 |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | PIK3CD 2727/4885PIK3CG 3429/4885PIK3CB 2522/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | PIK3CD 2727/4885PIK3CG 3429/4885PIK3CB 2522/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | PIK3CD 2395/4885PIK3CG 2700/4885PIK3CB 1926/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PIK3CD 23/4885PIK3CG 45/4885PIK3CB 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.